Lilly said it launched Foundayo, its oral obesity pill, pushing the oral GLP-1 race into a new phase against Novo Nordisk’s Wegovy tablet. The company won FDA approval for Foundayo last week, and introduced pricing at $149 per month for self-pay patients at the lowest dose, matching the starter price Novo set for Wegovy. The report noted both companies are preparing for the July 1 expansion of Medicare coverage for GLP-1 medicines and are lowering Medicare prices as part of a government deal to avoid tariffs. Lilly also highlighted dosing convenience versus oral Wegovy’s empty-stomach requirement. The launch sets up a near-term competitive test of how much incremental demand oral options capture versus cannibalizing existing injectable sales, as payers and distribution partners gear up for broader access.